# US 2023/0414614 A1 · Methods of treating disorders using csf1r inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414614 A1
- Document ID: US20230414614A1
- Status: Published application
- Kind: A1
- Application number: 18/140,942
- Filed: 2023-04-28
- Published: 2023-12-28
- Earliest claimed: 2018-12-28
- Assignees: Deciphera Pharmaceuticals, LLC
- Applicants: Deciphera Pharmaceuticals, LLC
- Inventors: Daniel L. Flynn; Bryan D. Smith; Rodrigo Ruiz Soto; Keisuke Kuida
- Web page: https://patentgrep.com/patent/US20230414614A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4523: containing further heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N 2333/7153: or colony-stimulating factors [CSF]
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound represented by:
wherein after 1 month or more of administration, the patient has: (i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or (ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.

### Claim 32 (depends on 31)

The method of claim 31, wherein the tumor is benign.

### Claim 33 (depends on 31)

The method of claim 31, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.

### Claim 34 (depends on 31)

The method of claim 31, wherein the therapeutically effective amount is about 2 mg to about 60 mg of the compound twice weekly.

### Claim 35 (depends on 31)

The method of claim 31, wherein the therapeutically effective amount is about 5 mg to about 30 mg of the compound twice weekly.

### Claim 36 (depends on 31)

The method of claim 31, comprising administering to the patient the compound twice weekly for about 3 months.

### Claim 37 (depends on 31)

The method of claim 31, comprising administering to the patient the compound twice weekly for about 6 months.

### Claim 38 (depends on 31)

The method of claim 31, comprising administering to the patient the compound twice weekly for about 1 year.

### Claim 39 (depends on 31)

The method of claim 31, comprising administering to the patient the compound twice weekly for about 2 years.

### Claim 40

A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient 30 mg of a compound represented by:
twice weekly, wherein after 1 month or more of administration, the patient has:
(i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or
(ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.

### Claim 41 (depends on 40)

The method of claim 40, wherein the tumor is benign.

### Claim 42 (depends on 40)

The method of claim 40, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.

### Claim 43 (depends on 40)

The method of claim 40, comprising administering to the patient the compound twice weekly for about 3 months.

### Claim 44 (depends on 40)

The method of claim 40, comprising administering to the patient the compound twice weekly for about 6 months.

### Claim 45 (depends on 40)

The method of claim 40, comprising administering to the patient the compound twice weekly for about 1 year.

### Claim 46 (depends on 40)

The method of claim 40, comprising administering to the patient the compound twice weekly for about 2 years.
